New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Oncology
Enobosarm Gets Fast Track Status for AR+ER+HER2- Metastatic Breast Cancer
Enobosarm is an oral, first-in-class, selective androgen receptor agonist.
Relatlimab-Nivolumab Ups PFS in Untreated Advanced Melanoma
Combination provides greater benefit than nivolumab alone for progression-free survival in untreated metastatic or unresectable melanoma
Maternal Hormonal Contraception, CNS Tumors Not Linked in Children
No significant association seen for recent or previous maternal hormonal contraception use with CNS tumors in children younger than 20 years
Patritumab Deruxtecan Gets Breakthrough Tx Status for Metastatic EGFR-Mutated NSCLC
Patritumab deruxtecan consists of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
HHS Carcinogen Report Updated to Include 8 Substances
The US Department of HHS added 8 new substances to the 15th Report on Carcinogens, bringing the total list to 256 substances.
Many Believe Dietary Supplements Cut Risk for Cancer Recurrence
Among adults diagnosed with breast, prostate, or colorectal cancer, 40 percent report using dietary supplements
Silmitasertib Granted Orphan Drug Status for Medulloblastoma
Silmitasertib is a first-in-class potent and highly selective inhibitor of casein kinase 2 (CK2).
Tocilizumab Shortage Prompts Temporary REMS Change for CAR T-Cell Therapy
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
CAR-T Therapy May Improve Outcomes in Second-Line Relapsed/Refractory LBCL
Researchers sought to determine whether lisocabtagene maraleucel would improve outcomes compared with standard of care in second-line therapy in patients with LBCL.
